UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 235

Sortiert nach

The Universal Character of the Tumor-Associated Antigen Survivin

Clinical cancer research, 2007-10, Vol.13 (20), p.5991-5994

2007

Link zum Volltext

Verfügbarkeit prüfen

The T-win® technology: immune-modulating vaccines

Seminars in immunopathology, 2019-01, Vol.41 (1), p.87-95

Andersen, Mads Hald

2019

Link zum Volltext

Verfügbarkeit prüfen

Anti-cancer immunotherapy: breakthroughs and future strategies

Seminars in immunopathology, 2019-01, Vol.41 (1), p.1-3

Andersen, Mads Hald

2019

Link zum Volltext

Verfügbarkeit prüfen

The effect of short-chain fatty acids on human monocyte-derived dendritic cells

Scientific reports, 2015-11, Vol.5 (1), p.16148-16148, Article 16148

2015

Link zum Volltext

Verfügbarkeit prüfen

Immune-suppressive properties of the tumor microenvironment

Cancer Immunology, Immunotherapy, 2013-07, Vol.62 (7), p.1137-1148

2013

Link zum Volltext

Verfügbarkeit prüfen

Butyrate and propionate inhibit antigen-specific CD8 + T cell activation by suppressing IL-12 production by antigen-presenting cells

Scientific reports, 2017-11, Vol.7 (1), p.14516-10, Article 14516

2017

Link zum Volltext

Verfügbarkeit prüfen

The targeting of tumor-associated macrophages by vaccination

Cell Stress, 2019-04, Vol.3 (5), p.139-140

Andersen, Mads Hald

2019

Link zum Volltext

Verfügbarkeit prüfen

Cytotoxic T Cells

Journal of investigative dermatology, 2006-01, Vol.126 (1), p.32-41

2006

Link zum Volltext

Verfügbarkeit prüfen

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens

Cancers, 2020-10, Vol.12 (10), p.3045

2020

Link zum Volltext

Verfügbarkeit prüfen

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

Cancer Immunology, Immunotherapy, 2012-10, Vol.61 (10), p.1791-1804

2012

Link zum Volltext

Verfügbarkeit prüfen

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

Cancer Immunology, Immunotherapy, 2019-11, Vol.68 (11), p.1901-1907

2019

Link zum Volltext

Verfügbarkeit prüfen

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (6), p.1764-1776

2013

Link zum Volltext

Verfügbarkeit prüfen

Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report

Frontiers in immunology, 2018-09, Vol.9, p.2145-2145

2018

Link zum Volltext

Verfügbarkeit prüfen

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

Frontiers in immunology, 2022-10, Vol.13, p.1023023-1023023

2022

Link zum Volltext

Verfügbarkeit prüfen

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms

Cancers, 2020-07, Vol.12 (7), p.1763

2020

Link zum Volltext

Verfügbarkeit prüfen

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

Oncoimmunology, 2022-12, Vol.11 (1), p.2115655-2115655

2022

Link zum Volltext

Verfügbarkeit prüfen

The expression, function and targeting of haem oxygenase-1 in cancer

Current cancer drug targets, 2014-01, Vol.14 (4), p.337

2014

Link zum Volltext

Verfügbarkeit prüfen

Tumor microenvironment antigens

Seminars in immunopathology, 2023-03, Vol.45 (2), p.253-264

Andersen, Mads Hald

2023

Link zum Volltext

Verfügbarkeit prüfen

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

Frontiers in immunology, 2020-09, Vol.11, p.578349-578349

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow

Frontiers in immunology, 2023-08, Vol.14, p.1240678-1240678

2023

Link zum Volltext

Verfügbarkeit prüfen

Cancer immune therapy for lymphoid malignancies: recent advances

Seminars in immunopathology, 2019-01, Vol.41 (1), p.111-124

2019

Link zum Volltext

Verfügbarkeit prüfen

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Journal for immunotherapy of cancer, 2023-05, Vol.11 (5), p.e006755

2023

Link zum Volltext

Verfügbarkeit prüfen

TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008405

2024

Link zum Volltext

Verfügbarkeit prüfen

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

Oncoimmunology, 2018-01, Vol.7 (6), p.e1433521-e1433521

2018

Link zum Volltext

Verfügbarkeit prüfen

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Frontiers in immunology, 2023-06, Vol.14, p.1180997-1180997

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 235

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(219)
Mit Volltextzugriff
(226)

Publikationsform

Sprache

Englisch
(232)
Japanisch
(11)
Dänisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(161)
Life Sciences & Biomedicine
(156)
Humans
(122)
Oncology
(95)
Immunology
(94)
Immunotherapy
(58)
Cancer
(51)
Lymphocytes
(42)
Neoplasms - Immunology
(37)
Biological And Medical Sciences
(33)
Medical Sciences
(33)
Melanoma
(32)
Vaccination
(32)
Antigens
(31)
Melanoma - Immunology
(31)
Peptides
(30)
Tumors
(30)
Antigens, Neoplasm - Immunology
(28)
Animals
(26)
T-Lymphocytes, Cytotoxic - Immunology
(25)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

The Universal Character of the Tumor-Associated Antigen Survivin

The T-win® technology: immune-modulating vaccines

Anti-cancer immunotherapy: breakthroughs and future strategies

The effect of short-chain fatty acids on human monocyte-derived dendritic cells

Immune-suppressive properties of the tumor microenvironment

Butyrate and propionate inhibit antigen-specific CD8 + T cell activation by suppressing IL-12 production by antigen-presenting cells

The targeting of tumor-associated macrophages by vaccination

Cytotoxic T Cells

Healthy Donors Harbor Memory T Cell Responses to RAS Neo-Antigens

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope

HLA-Restricted CTL That Are Specific for the Immune Checkpoint Ligand PD-L1 Occur with High Frequency in Cancer Patients

Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report

Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors – A phase I trial

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms

CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment

The expression, function and targeting of haem oxygenase-1 in cancer

Tumor microenvironment antigens

Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow

Cancer immune therapy for lymphoid malignancies: recent advances

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

TGFβ-specific T cells induced by a TGFβ-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response

Ex vivo modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Suchergebnisse filtern